Answers are grounded in this paper and cite their sources.
Although immunotherapies have improved outcomes in multiple myeloma (MM), therapeutic resistance remains a major challenge, thereby underscoring the need for strategies that enhance tumor immunogenicity. Here, we show that cardiac glycosides (CGs), including periplocin and digoxin, act as immunogenic sensitizers in MM. CG treatment upregulated the cell‐surface expression of ICAM‐1, 4‐1BBL, and SLAMF7 in MM cell lines and primary patient‐derived CD138 + cells. Mechanistically, our findings support the involvement of Na + /K + ‐ATPase inhibition, Ca 2+ signaling, and mitochondrial‐ and endoplasmic reticulum (ER)‐associated ROS pathways in CG‐induced immune remodeling. CGs also induced immunogenic cell death (ICD)‐associated changes, including cell‐surface calreticulin exposure and extracellular HMGB1 and ATP release. These changes were associated with ferroptosis, as indicated by intracellular Fe 2+ accumulation, lipid peroxidation, elevated malondialdehyde levels, and attenuation of ICD markers by ferroptosis inhibitors. Functionally, CG treatment enhanced the cytotoxic effects of elotuzumab and teclistamab by promoting effector T‐ and NK‐cell‐mediated killing. Collectively, our findings suggest that the Na + /K + ‐ATPase–Ca 2+ –ROS axis contributes to immune remodeling and ferroptosis‐associated ICD in MM. These results provide mechanistic insights into stress‐induced tumor immunogenicity and support further investigation of CGs as sensitizers for antibody‐based immunotherapy in MM.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: